We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+7.32%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
-$130M
(-7.3%)
Cap. Flow
-$202M
Cap. Flow
% of AUM
-12.26%
Top 10 Holdings %
Top 10 Hldgs %
56.48%
Holding
64
New
19
Increased
12
Reduced
10
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$98.3M |
| 2 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$93.8M |
| 3 |
Zimmer Biomet
ZBH
|
+$90.7M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$61.2M |
| 5 |
DexCom
DXCM
|
+$60.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$129M |
| 2 |
Edwards Lifesciences
EW
|
+$113M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$108M |
| 4 |
RAD
Rite Aid Corporation
RAD
|
+$82.1M |
| 5 |
AET
Aetna Inc
AET
|
+$71.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.96% |
| 2 | Financials | 0% |
| 3 | Industrials | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KND
26
DELISTED
Kindred Healthcare
KND
| $16.7M | 1.01% |
+1,400,000
| New | +$18.1M |
|
27
Biogen
BIIB
$30B
| $14.4M | 0.88% |
+47,090
| New | +$13.5M |
|
28
Merck
MRK
$322B
| $12.4M | 0.76% |
+246,741
| New | +$12.4M |
|
|
ALXN
29
DELISTED
Alexion Pharmaceuticals
ALXN
| $11.4M | 0.69% |
59,890
-390,110
| -87% | -$68.1M |
|
30
AbbVie
ABBV
$443B
| $11.2M | 0.68% |
+188,600
| New | +$10.9M |
|
|
SPNE
31
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $10.4M | 0.63% |
604,000
+104,000
| +21% | +$1.64M |
|
32
Arbutus Biopharma
ABUS
$857M
| $9.74M | 0.59% |
2,189,200
+39,200
| +2% | +$215K |
|
|
33
Edwards Lifesciences
EW
$49.6B
| $7.56M | 0.46% |
287,280
-4,362,720
| -94% | -$113M |
|
34
Natera
NTRA
$38.3B
| $2.97M | 0.18% |
275,000
+20,000
| +8% | +$190K |
|
|
HSTO
35
DELISTED
Histogen Inc. Common Stock
HSTO
| $2.96M | 0.18% |
5,135
+92
| +2% | +$64.5K |
|
36
Tandem Diabetes Care
TNDM
$1.34B
| $2.3M | 0.14% |
19,511
-3,069
| -14% | -$304K |
|
37
Pacira BioSciences
PCRX
$1.04B
| $1.65M | 0.1% |
+21,500
| New | +$1.22M |
|
38
UnitedHealth
UNH
$376B
| $959K | 0.06% |
+8,150
| New | +$953K |
|
39
HCA Healthcare
HCA
$87.2B
| $756K | 0.05% |
11,180
-563,820
| -98% | -$39.3M |
|
40
Align Technology
ALGN
$12.1B
| $527K | 0.03% |
+8,000
| New | +$513K |
|
41
Amgen
AMGN
$208B
| $365K | 0.02% |
+2,250
| New | +$354K |
|
42
Zoetis
ZTS
$32.4B
| $288K | 0.02% |
+6,000
| New | +$271K |
|
43
CALL
Agilent Technologies
A
$39.1B
| – | – |
-1,000,000
| Closed | -$34.3M |
|
|
44
Agilent Technologies
A
$39.1B
| – | – |
-325,500
| Closed | -$11.2M |
|
45
Assembly Biosciences
ASMB
$498M
| – | – |
-26,552
| Closed | -$3.05M |
|
|
CPRX
46
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-385,500
| Closed | -$1.16M |
|
47
McKesson
MCK
$100B
| – | – |
-275,000
| Closed | -$50.9M |
|
48
Neurocrine Biosciences
NBIX
$16.8B
| – | – |
-150,000
| Closed | -$5.97M |
|
49
CALL
Pfizer
PFE
$143B
| – | – |
-1,054,000
| Closed | -$31.4M |
|
50
United Therapeutics
UTHR
$25.8B
| – | – |
-170,400
| Closed | -$22.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2015 Portfolio in Review
As of Q4 2015, HealthCor Management held 64 positions worth $1.65B, down 7.3% from $1.78B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
HealthCor Management withdrew a net $202M in Q4 2015, closing 22 positions and reducing 10 holdings. Its most notable exit was Allergan plc, an estimated $129M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 61% a quarter earlier, followed by Financials and Industrials.
Against the trend, HealthCor Management opened a new position in Clovis Oncology, Inc. worth $53.4M.
- HealthCor Management's largest Q4 2015 buy was Clovis Oncology, Inc.: 1,525,000 shares worth $53.4M.
- HealthCor Management added most to DexCom in Q4 2015, an estimated $60.3M increase.
- HealthCor Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $113M.
- HealthCor Management fully exited Allergan plc in Q4 2015, selling an estimated $129M.
- HealthCor Management's ten largest holdings make up 56% of its $1.65B portfolio in Q4 2015.
- HealthCor Management opened 19 new positions and closed 22 in Q4 2015.
- HealthCor Management's portfolio value fell 7.3% quarter-over-quarter to $1.65B.
Based on HealthCor Management's 13F filing for Q4 2015, filed 16 Feb 2016.